2-Oct-2026
Aldeyra Therapeutics: Neutral Rating Maintained Amid FDA Uncertainty; $2 Price Target Reaffirmed
TipRanks (Wed, 30-Sep 6:25 AM ET)
ALDX Climbs as Aldeyra Plans FDA Formal Dispute Resolution Request for Reproxalap After Three CRLs
Market Chameleon (Tue, 29-Sep 7:05 AM ET)
Business Wire (Tue, 29-Sep 8:07 AM ET)
Aldeyra Therapeutics to Host Regulatory Update Webcast
Business Wire (Tue, 29-Sep 8:06 AM ET)
Aldeyra Pursues FDA Dispute Over Dry Eye Drug
TipRanks (Tue, 29-Sep 7:30 AM ET)
Aldeyra Therapeutics to appeal FDA rejection of dry eye disease drug reproxalap
Seeking Alpha News (Tue, 29-Sep 7:13 AM ET)
Levicept Appoints Darlene Deptula-Hicks as CFO
Globe Newswire (Tue, 7-Jul 4:00 AM ET)
ALDX Faces Securities Class Action Investigation Amid FDA Setback—What Should Investors Watch Now?
Market Chameleon (Mon, 23-Mar 7:44 AM ET)
ALDX Faces Class Action After 70% Stock Decline Follows FDA Setback on Lead Drug
Market Chameleon (Thu, 19-Mar 6:35 AM ET)
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Aldeyra Therapeutics trades on the NASDAQ stock market under the symbol ALDX.
As of October 2, 2026, ALDX stock price declined to $1.17 with 2,217,847 million shares trading.
ALDX has a beta of 3.14, meaning it tends to be more sensitive to market movements. ALDX has a correlation of 0.14 to the broad based SPY ETF.
ALDX has a market cap of $70.58 million. This is considered a Micro Cap stock.
Last quarter Aldeyra Therapeutics reported $0 in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-47 million and missed earnings estimates by -$.01.
In the last 3 years, ALDX traded as high as $7.20 and as low as $1.07.
The top ETF exchange traded funds that ALDX belongs to (by Net Assets): VTI, VXF, VHT, IWC, PRFZ.
ALDX has underperformed the market in the last year with a price return of -78.0% while the SPY ETF gained +16.1%. ALDX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -48.5% and -14.0%, respectively, while the SPY returned +3.6% and +1.0%, respectively.
ALDX support price is $1.22 and resistance is $1.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALDX shares will trade within this expected range on the day.
